Merck & Co., Inc. $MRK Holdings Raised by Root Financial Partners LLC

Root Financial Partners LLC boosted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 30.6% during the third quarter, Holdings Channel.com reports. The firm owned 15,805 shares of the company’s stock after buying an additional 3,703 shares during the quarter. Root Financial Partners LLC’s holdings in Merck & Co., Inc. were worth $2,297,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of MRK. Susquehanna Fundamental Investments LLC purchased a new position in Merck & Co., Inc. in the second quarter worth approximately $11,470,000. Russell Investments Group Ltd. increased its stake in Merck & Co., Inc. by 2.0% during the second quarter. Russell Investments Group Ltd. now owns 2,578,024 shares of the company’s stock worth $331,931,000 after acquiring an additional 51,393 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in Merck & Co., Inc. by 7.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,184,340 shares of the company’s stock valued at $794,577,000 after purchasing an additional 402,011 shares during the period. The Manufacturers Life Insurance Company raised its position in Merck & Co., Inc. by 12.3% in the second quarter. The Manufacturers Life Insurance Company now owns 2,073,176 shares of the company’s stock valued at $266,403,000 after purchasing an additional 227,589 shares during the period. Finally, Talon Private Wealth LLC purchased a new stake in Merck & Co., Inc. in the second quarter valued at $995,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Merck & Co., Inc.

In other news, EVP David Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the transaction, the executive vice president owned 31,716 shares in the company, valued at approximately $4,084,069.32. This trade represents a 62.49% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Richard R. Deluca sold 11,699 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total value of $1,539,939.37. Following the transaction, the executive vice president directly owned 110,167 shares of the company’s stock, valued at approximately $14,501,282.21. This represents a 9.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 228,238 shares of company stock worth $29,977,783 over the last quarter. 0.17% of the stock is currently owned by insiders.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported Phase 3 INTerpath-001 results showing that intismeran autogene combined with KEYTRUDA reduced the risk of melanoma recurrence or death by 42%, while also improving distant metastasis-free survival. The data met market expectations and could support a future expansion of Merck’s oncology pipeline beyond KEYTRUDA. Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
• Positive Sentiment: The European Commission approved KEYTRUDA plus Padcev as perioperative treatment for adults with resectable muscle-invasive bladder cancer. The wider label expands the addressable market for Merck’s leading oncology franchise and may help offset future pressure from slowing KEYTRUDA growth. European Commission approves KEYTRUDA plus Padcev
• Neutral Sentiment: Trading activity included approximately 37,444 MRK call options, about 40% above average daily volume, indicating increased speculative interest but not establishing a clear direction for the shares.
• Negative Sentiment: An apparent early leak of the melanoma-vaccine data caused volatility and appears to have prompted profit-taking. Investors may have expected a larger-than-reported benefit despite the statistically and clinically positive results, creating a sell-the-news response ahead of the formal ESMO presentation. Moderna, Merck shares fall after possible melanoma data leak
• Negative Sentiment: Analysts expect Merck’s upcoming third-quarter earnings to decline, limiting near-term enthusiasm and reinforcing concerns about moderating KEYTRUDA growth. Zacks also reportedly downgraded MRK from “hold” to “strong sell,” adding pressure to sentiment.

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $147.40 on Friday. The company has a fifty day simple moving average of $146.79 and a two-hundred day simple moving average of $130.07. The company has a market cap of $363.67 billion, a price-to-earnings ratio of 117.92, a price-to-earnings-growth ratio of 6.92 and a beta of 0.21. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a 52 week low of $82.01 and a 52 week high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The business had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The company’s revenue was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 2.66 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is presently 272.00%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on MRK shares. Barclays increased their price target on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Rothschild & Co Redburn raised their price objective on Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a “buy” rating in a research report on Monday, July 6th. Royal Bank Of Canada reduced their price objective on shares of Merck & Co., Inc. from $150.00 to $145.00 and set a “sector perform” rating on the stock in a report on Monday, October 12th. The Goldman Sachs Group upped their target price on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the company a “buy” rating in a research report on Friday, August 21st. Finally, Wolfe Research increased their target price on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 25th. Seventeen equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average target price of $151.92.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.